WEF-001

WEF-001 is a novel anticancer agent composed of a conjugate between human serum albumin and the cytotoxic payload monomethyl auristatin E (MMAE). It is designed for targeted delivery to tumor cells with KRAS mutations via increased pinocytosis, leveraging cancer cells' propensity to engulf albumin and thereby enhancing intracellular delivery of MMAE. The molecule functions as a tubulin inhibitor, disrupting microtubule formation and resulting in apoptotic cancer cell death. WEF-001 is in clinical trials for advanced solid tumors with KRAS mutations, including pancreatic, colorectal, non-small cell lung cancer, platinum-resistant serous ovarian cancer, cholangiocarcinoma, and urothelial bladder cancer. The drug was originally developed by Syndivia and later spun into Auricula Biosciences, co-founded by TVM Life Science and Lilly[2][5][7][9][10].

Brand names

WEF-001WEF001WEF 001

Other names

WEF-001WEF001WEF 001SDV1001SDV-1001SDV 1001